Elidel
® (
pimecrolimus) is a prescription medication approved to treat mild-to-moderate
atopic dermatitis (commonly referred to as eczema) in certain people who have not adequately responded to other treatments or cannot use other treatments. It comes in the form of a cream that is applied directly to the skin. Elidel can be used in adults and children as young as two years old.
Elidel is made by Novartis Pharma Produktions GmbH for Novartis Pharmaceuticals, Corp.
Atopic dermatitis is thought to occur when the immune system has an overactive response to a trigger, leading to symptoms such as redness, a rash, and itching. Elidel is an "immunosuppressant" medication, which means it reduces the activity of the immune system. By making the immune system less active, Elidel can relieve the
symptoms of atopic dermatitis.
In clinical studies, Elidel has been shown to improve symptoms of mild-to-moderate atopic dermatitis in children and adults. In these studies, 35 percent of people using Elidel were clear or almost clear of symptoms after six weeks of treatment, compared to 18 percent of people using a cream that did not contain any active ingredients (a placebo cream). In addition, 57 percent of the Elidel group had mild to no itching after six weeks, compared to 34 percent of the placebo group.